JP5504171B2 - Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド - Google Patents

Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド Download PDF

Info

Publication number
JP5504171B2
JP5504171B2 JP2010540046A JP2010540046A JP5504171B2 JP 5504171 B2 JP5504171 B2 JP 5504171B2 JP 2010540046 A JP2010540046 A JP 2010540046A JP 2010540046 A JP2010540046 A JP 2010540046A JP 5504171 B2 JP5504171 B2 JP 5504171B2
Authority
JP
Japan
Prior art keywords
phenyl
oxo
pyrazole
carbonyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010540046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011507915A5 (enExample
JP2011507915A (ja
Inventor
マルク・ナツァレ
ゲーアノト・ツェッヒ
メリッタ・ユースト
チロ・ヴァイス
ゲーアハルト・ヘスラー
マルクス・コールマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2011507915A publication Critical patent/JP2011507915A/ja
Publication of JP2011507915A5 publication Critical patent/JP2011507915A5/ja
Application granted granted Critical
Publication of JP5504171B2 publication Critical patent/JP5504171B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2010540046A 2007-12-26 2008-12-12 Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド Expired - Fee Related JP5504171B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07291627 2007-12-26
EP07291627.3 2007-12-26
PCT/EP2008/010572 WO2009080226A2 (en) 2007-12-26 2008-12-12 Heterocyclic pyrazole-carboxamides as p2y12 antagonists

Publications (3)

Publication Number Publication Date
JP2011507915A JP2011507915A (ja) 2011-03-10
JP2011507915A5 JP2011507915A5 (enExample) 2012-02-02
JP5504171B2 true JP5504171B2 (ja) 2014-05-28

Family

ID=39521970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010540046A Expired - Fee Related JP5504171B2 (ja) 2007-12-26 2008-12-12 Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド

Country Status (4)

Country Link
US (1) US8426420B2 (enExample)
EP (1) EP2238128B1 (enExample)
JP (1) JP5504171B2 (enExample)
WO (1) WO2009080226A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20120735T1 (hr) 2007-11-29 2012-10-31 Actelion Pharmaceuticals Ltd. Derivati fosfonske kiseline i njihova uporaba kao antagonista p2y12 receptora
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
ES2567311T3 (es) 2009-04-08 2016-04-21 Actelion Pharmaceuticals Ltd. 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP
JP5536876B2 (ja) 2009-04-22 2014-07-02 アクテリオン ファーマシューティカルズ リミテッド チアゾール誘導体及びｐ２ｙ１２受容体拮抗剤としてのそれらの使用
UY33200A (es) 2010-01-26 2011-08-31 Sanofi Aventis Derivados de ácido 3-heteroaroilamino-propiónico sustituidos con oxígeno y su uso como productos farmacéuticos
TWI523844B (zh) 2011-01-26 2016-03-01 賽諾菲公司 經胺基取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
US8669370B2 (en) 2011-01-26 2014-03-11 Sanofi Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
FR2974576B1 (fr) * 2011-04-29 2013-07-19 Sanofi Aventis Derives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide, leur preparation et leurs applications en therapeutique
KR20140049020A (ko) 2011-07-26 2014-04-24 사노피 치환된 ３-（티아졸-４-카보닐）- 또는 ３-（티아졸-２-카보닐）아미노프로피온산 유도체 및 이의 약제로서의 용도
CN105646362B (zh) 2011-07-26 2019-07-05 赛诺菲 3-杂芳酰基氨基-丙酸衍生物及其作为药物的用途
EP2750676B1 (en) 2011-08-30 2018-01-10 University of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
WO2013072328A1 (en) 2011-11-14 2013-05-23 Sanofi Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
US20130123325A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
HK1212348A1 (en) 2012-12-19 2016-06-10 Novartis Ag Autotaxin inhibitors
SG11201506292XA (en) 2013-03-28 2015-09-29 Sanofi Sa Biaryl-propionic acid derivatives and their use as pharmaceuticals
WO2014154726A1 (en) 2013-03-28 2014-10-02 Sanofi Biaryl-propionic acid derivatives and their use as pharmaceuticals
CN104109158A (zh) * 2013-04-16 2014-10-22 上海医药工业研究院 一种纯化利伐沙班的方法
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
CN107759662B (zh) * 2013-08-28 2020-10-30 北京赛而生物药业有限公司 一种抗凝血化合物、其制备方法和用途、及包含其的药物组合物
US9231217B2 (en) 2013-11-28 2016-01-05 Semiconductor Energy Laboratory Co., Ltd. Synthesis method of organometallic complex, synthesis method of pyrazine derivative, 5,6-diaryl-2-pyrazyl triflate, light-emitting element, light-emitting device, electronic device, and lighting device
PL3515924T3 (pl) 2016-09-22 2022-04-11 Idorsia Pharmaceuticals Ltd Krystaliczne postacie
BR112019014567A2 (pt) 2017-03-15 2020-02-18 Idorsia Pharmaceuticals Ltd Antagonista do receptor p2y12 ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de éster butílico do ácido
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
CN115298173A (zh) 2020-03-31 2022-11-04 田边三菱制药株式会社 羟基吡咯烷衍生物及其医药用途
CN115429874A (zh) * 2022-09-20 2022-12-06 暨南大学 水蛭素靶向并抑制dpp4治疗糖尿病
CN119930579A (zh) * 2025-01-15 2025-05-06 四川轻化工大学 哌啶环类化合物及其合成方法、药学上可接受的盐与应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5621359A (en) * 1995-07-27 1997-04-15 Lucent Technologies Inc. Gain selection technique
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
WO2000077027A2 (en) 1999-06-14 2000-12-21 Tularik Limited Serine protease inhibitors
KR20010083092A (ko) 1998-07-06 2001-08-31 스티븐 비. 데이비스 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
AU2002341693B2 (en) 2001-09-21 2008-05-29 Bristol-Myers Squibb Holdings Ireland Unlimited Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
CA2511321A1 (en) * 2002-12-23 2004-07-08 Aventis Pharma Deutschland Gmbh Pyrazole-derivatives as factor xa inhibitors
GB0309637D0 (en) * 2003-04-28 2003-06-04 Cancer Rec Tech Ltd Pyrazole compounds
AU2003249865A1 (en) 2003-06-24 2005-01-21 Actelion Pharmaceuticals Ltd Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
US7441581B2 (en) * 2005-03-10 2008-10-28 3M Innovative Properties Company Adhesive tape applicator
TW200640877A (en) * 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives

Also Published As

Publication number Publication date
US20110021537A1 (en) 2011-01-27
WO2009080226A3 (en) 2009-08-27
EP2238128A2 (en) 2010-10-13
US8426420B2 (en) 2013-04-23
EP2238128B1 (en) 2012-08-22
JP2011507915A (ja) 2011-03-10
WO2009080226A2 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
JP5504171B2 (ja) Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
JP5560202B2 (ja) Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体
US8669266B2 (en) Quinoline-carboxamide derivatives as P2Y12 antagonists
JP4861306B2 (ja) Ｘａ因子阻害剤としてのピロール誘導体
JP4709763B2 (ja) 第Ｘａ因子阻害剤としてのインダゾール誘導体
JP4585448B2 (ja) 第Ｘａ因子阻害剤としてのピラゾール−誘導体
KR20060136457A (ko) 인자 Ｘａ 억제제로서의 피롤-유도체
EA011245B1 (ru) Амиды карбоновых кислот в качестве ингибиторов фактора ха
US20050009827A1 (en) Triazole-derivatives as factor Xa inhibitors
JP2007535497A (ja) 第Ｘａ因子阻害剤としてのβ−アミノ酸誘導体
CN101309919A (zh) 作为凝血因子xa抑制剂的新的吡咯烷衍生物
JP4608495B2 (ja) 第Ｘａ因子阻害剤としてのトリアゾール誘導体
JP5422569B2 (ja) 凝固第Ｘａ因子及びトロンビンの阻害剤としてのクロロチオフェン−イソオキサゾール類
KR20060014056A (ko) 인자 Ｘａ 억제제로서의 벤즈이미다졸 유도체
KR20060012636A (ko) 인자 Ｘａ 억제제로서의 아자인돌 유도체
KR101373533B1 (ko) 인자 Ｘａ 억제제로서의 헤테로아릴-카복실산(설파모일 알킬)아미드 유도체
HK1141803B (en) Quinoline-carboxamide derivatives as p2y12 antagonists
HK1089174B (en) Benzimidazole-derivatives as factor xa inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140317

R150 Certificate of patent or registration of utility model

Ref document number: 5504171

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees